Invention Grant
- Patent Title: IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
-
Application No.: US15120214Application Date: 2015-02-20
-
Publication No.: US10010587B2Publication Date: 2018-07-03
- Inventor: Murali Krishna Addepalli , Deborah H. Charych , Seema Kantak , Steven Robert Lee
- Applicant: Nektar Therapeutics , NEKTAR THERAPEUTICS (INDIA) PVT. LTD.
- Applicant Address: US CA San Francisco
- Assignee: Nektar Therapeutics
- Current Assignee: Nektar Therapeutics
- Current Assignee Address: US CA San Francisco
- Agent Susan T. Evans
- Priority: IN499/DEL/2014 20140221; IN3087/DEL/2014 20141029
- International Application: PCT/IN2015/000099 WO 20150220
- International Announcement: WO2015/125159 WO 20150827
- Main IPC: A61K38/20
- IPC: A61K38/20 ; A61K39/395 ; A61K47/48 ; C07K16/28 ; C07K16/30
Abstract:
The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2Rβ-activating amount of a long acting, IL-2Rβ-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
Public/Granted literature
- US20170128539A1 IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY Public/Granted day:2017-05-11
Information query
IPC分类:
